BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhandari S, Galanello R. Renal aspects of thalassaemia a changing paradigm. Eur J Haematol 2012;89:187-97. [DOI: 10.1111/j.1600-0609.2012.01819.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Demosthenous C, Vlachaki E, Apostolou C, Eleftheriou P, Kotsiafti A, Vetsiou E, Mandala E, Perifanis V, Sarafidis P. Beta-thalassemia: renal complications and mechanisms: a narrative review. Hematology 2019;24:426-38. [PMID: 30947625 DOI: 10.1080/16078454.2019.1599096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
2 Tantawy AA, El Bablawy N, Adly AA, Ebeid FS. Early Predictors of Renal Dysfunction in Egyptian Patients with β-Thalassemia Major and Intermedia. Mediterr J Hematol Infect Dis 2014;6:e2014057. [PMID: 25237470 DOI: 10.4084/MJHID.2014.057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yatmark P, Morales NP, Chaisri U, Wichaiyo S, Hemstapat W, Srichairatanakool S, Svasti S, Fucharoen S. Iron distribution and histopathological study of the effects of deferoxamine and deferiprone in the kidneys of iron overloaded β-thalassemic mice. Experimental and Toxicologic Pathology 2016;68:427-34. [DOI: 10.1016/j.etp.2016.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 Al-Okbi SY, Mohamed DA, Hamed TE, Esmail RSh, Donya SM. Prevention of renal dysfunction by nutraceuticals prepared from oil rich plant foods. Asian Pac J Trop Biomed 2014;4:618-27. [PMID: 25183331 DOI: 10.12980/APJTB.4.201414B66] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 van Raaij SEG, Rennings AJ, Biemond BJ, Schols SEM, Wiegerinck ETG, Roelofs HMJ, Hoorn EJ, Walsh SB, Nijenhuis T, Swinkels DW, van Swelm RPL. Iron handling by the human kidney: glomerular filtration and tubular reabsorption both contribute to urinary iron excretion. Am J Physiol Renal Physiol 2019;316:F606-14. [PMID: 30623722 DOI: 10.1152/ajprenal.00425.2018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013;128:281-308. [PMID: 23775258 DOI: 10.1161/cir.0b013e31829b2be6] [Cited by in Crossref: 187] [Cited by in F6Publishing: 71] [Article Influence: 20.8] [Reference Citation Analysis]
7 Wong P, Polkinghorne K, Kerr PG, Doery JC, Gillespie MT, Larmour I, Fuller PJ, Bowden DK, Milat F. Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone 2016;85:55-8. [DOI: 10.1016/j.bone.2016.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
8 Kassianides X, Hazara AM, Bhandari S. Improving the safety of intravenous iron treatments for patients with chronic kidney disease. Expert Opin Drug Saf 2021;20:23-35. [PMID: 33203251 DOI: 10.1080/14740338.2021.1853098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Fradette C, Pichette V, Sicard É, Stilman A, Jayashankar S, Tsang YC, Spino M, Tricta F. Effects of renal impairment on the pharmacokinetics of orally administered deferiprone. Br J Clin Pharmacol 2016;82:994-1001. [PMID: 27276421 DOI: 10.1111/bcp.13037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Deveci B, Kurtoglu A, Kurtoglu E, Salim O, Toptas T. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia. Ann Hematol 2016;95:375-81. [PMID: 26596972 DOI: 10.1007/s00277-015-2561-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
11 van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol 2020;16:77-98. [PMID: 31554933 DOI: 10.1038/s41581-019-0197-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
12 Zanella S, Garani MC, Borgna-pignatti C. Malignancies and thalassemia: a review of the literature: Malignancies and thalassemia. Ann N Y Acad Sci 2016;1368:140-8. [DOI: 10.1111/nyas.13005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yavuz S, Anarat A, Bayazıt AK, Karagun BŞ, Yılmaz S, Kılınc Y, Gonlusen G, Kuyucu Y. Membranous nephropathy presenting with nephrotic syndrome in a child with thalassemia major. Pediatr Int 2015;57:711-3. [PMID: 25711242 DOI: 10.1111/ped.12572] [Reference Citation Analysis]
14 Al-khabori M, Bhandari S, Al-rasadi K, Mevada S, Al-dhuhli H, Al-kemyani N, Daar S. Correlation of Iron Overload and Glomerular Filtration Rate Estimated by Cystatin C in Patients with β-Thalassemia Major. Hemoglobin 2014;38:365-8. [DOI: 10.3109/03630269.2014.944314] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
15 ElAlfy MS, Khalil Elsherif NH, Ebeid FSE, Ismail EAR, Ahmed KA, Darwish YW, Ibrahim AS, Elghamry IRF, Shokrey NA, Alajeil DN. Renal iron deposition by magnetic resonance imaging in pediatric β-thalassemia major patients: Relation to renal biomarkers, total body iron and chelation therapy. Eur J Radiol 2018;103:65-70. [PMID: 29803388 DOI: 10.1016/j.ejrad.2018.04.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Arman Bilir Ö, Kirkiz S, Fettah A, Ok Bozkaya İ, Kara A, Çakar N, Yaralı N. Renal function and the oxidative status among children with thalassemia major and healthy controls: A cross-sectional study. Transfus Apher Sci 2020;59:102746. [PMID: 32173278 DOI: 10.1016/j.transci.2020.102746] [Reference Citation Analysis]
17 Chalmers AW, Shammo JM. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin Risk Manag 2016;12:201-8. [PMID: 26929633 DOI: 10.2147/TCRM.S82449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
18 Piga A, Fracchia S, Lai ME, Cappellini MD, Hirschberg R, Habr D, Wegener A, Bouillaud E, Forni GL. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia. Br J Haematol 2015;168:882-90. [PMID: 25402221 DOI: 10.1111/bjh.13217] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
19 Tanous O, Azulay Y, Halevy R, Dujovny T, Swartz N, Colodner R, Koren A, Levin C. Renal function in β-thalassemia major patients treated with two different iron-chelation regimes. BMC Nephrol 2021;22:418. [PMID: 34930156 DOI: 10.1186/s12882-021-02630-5] [Reference Citation Analysis]
20 Tzoulis P, Shah F, Jones R, Prescott E, Barnard M. Joint Diabetes Thalassaemia Clinic: An Effective New Model of Care. Hemoglobin 2014;38:104-10. [DOI: 10.3109/03630269.2013.862541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 van Raaij SEG, Srai SKS, Swinkels DW, van Swelm RPL. Iron uptake by ZIP8 and ZIP14 in human proximal tubular epithelial cells. Biometals 2019;32:211-26. [PMID: 30806852 DOI: 10.1007/s10534-019-00183-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
22 Ricchi P, Meloni A, Grigoratos C, Toia P, Fina P, Pistoia L, Costantini S, Borsellino Z, Lisi R, Rocca M, Preziosi P, Midiri M, Pepe A. Prevalence of extramedullary hematopoiesis, renal cysts, splenic and hepatic lesions, and vertebral hemangiomas among thalassemic patients: a retrospective study from the Myocardial Iron Overload in Thalassemia (MIOT) network. Ann Hematol 2019;98:1333-9. [PMID: 30891614 DOI: 10.1007/s00277-019-03659-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Şen V, Ece A, Uluca Ü, Söker M, Güneş A, Kaplan İ, Tan İ, Yel S, Mete N, Sahin C. Urinary early kidney injury molecules in children with beta-thalassemia major. Ren Fail 2015;37:607-13. [PMID: 25656833 DOI: 10.3109/0886022X.2015.1007871] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Ricchi P, Ammirabile M, Costantini S, Spasiano A, Di Matola T, Cinque P, Casale M, Filosa A, Prossomariti L. Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters. Ann Hematol 2014;93:525-7. [PMID: 23807253 DOI: 10.1007/s00277-013-1833-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
25 Makmettakul S, Tantiworawit A, Phrommintikul A, Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L, Fanhchaksai K, Charoenkwan P, Lekawanvijit S. Cardiorenal syndrome in thalassemia patients. BMC Nephrol 2020;21:325. [PMID: 32746879 DOI: 10.1186/s12882-020-01990-8] [Reference Citation Analysis]
26 Santos MA, Chaves S. 3-Hydroxypyridinone derivatives as metal-sequestering agents for therapeutic use. Future Med Chem 2015;7:383-410. [PMID: 25826364 DOI: 10.4155/fmc.14.162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
27 Sadeghi MV, Mirghorbani M, Akbari R. β-Thalassemia minor & renal tubular dysfunction: is there any association? BMC Nephrol 2021;22:404. [PMID: 34872508 DOI: 10.1186/s12882-021-02602-9] [Reference Citation Analysis]
28 Hodroj MH, Bou-fakhredin R, Nour-eldine W, Noureldine HA, Noureldine MHA, Taher AT. Thalassemia and malignancy: An emerging concern? Blood Reviews 2019;37:100585. [DOI: 10.1016/j.blre.2019.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Bragadesh T, Bhandari S. Deferiprone, iron overload in a renal transplant patient. QJM 2014;107:465-6. [DOI: 10.1093/qjmed/hct254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Grassedonio E, Meloni A, Positano V, De Marchi D, Toia P, Midiri M, Pepe A. Quantitative T2* magnetic resonance imaging for renal iron overload assessment: normal values by age and sex. Abdom Imaging 2015;40:1700-4. [PMID: 25761947 DOI: 10.1007/s00261-015-0395-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
31 van Swelm RPL, Beurskens S, Dijkman H, Wiegerinck ETG, Roelofs R, Thévenod F, van der Vlag J, Wetzels JFM, Swinkels DW, Smeets B. Kidney tubule iron loading in experimental focal segmental glomerulosclerosis. Sci Rep 2022;12:1199. [PMID: 35075227 DOI: 10.1038/s41598-022-05261-4] [Reference Citation Analysis]
32 Kassianides X, Bhandari S. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs Context 2021;10:2020-11-3. [PMID: 33519940 DOI: 10.7573/dic.2020-11-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]